Tags

Type your tag names separated by a space and hit enter

Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine.
Clin Infect Dis. 1999 May; 28(5):1100-3.CI

Abstract

The current World Health Organization recommendation for booster vaccination of previously immunized individuals with potential exposure to rabies is two doses of vaccine intramuscularly or intradermally on days 0 and 3. We report responses to two types of postexposure treatment of healthy individuals who had received preexposure rabies vaccination 1 year previously. Group A individuals received four intradermal doses (one-fifth of the diluent volume of vaccine per dose) on day 0, and group B individuals received two intramuscular doses on days 0 and 3. Immunogenicity of the two booster regimens was assessed by titrating the amount of neutralizing antibody (Nab). We found that the booster doses of vaccine produced remarkable responses in all subjects. Nab titers of > or = 0.5 IU/mL (acceptable antibody level for protection against rabies) were detected in all subjects on day 14, and they were shown to be consistently high 1 year after the booster vaccination. We also found that the Nab titers for group A were significantly higher (two- to eightfold) than those for group B on days 5, 14, 150, and 360 after the initial booster vaccination (P < .05). Our study shows that the four-site intradermal booster regimen with use of one-fifth of the diluent volume of cell-culture rabies vaccine on day 0 is associated with a significantly higher antibody response than is the conventional booster regimen for subsequent postexposure rabies treatment of individuals who have received preexposure rabies vaccination with cell-culture rabies vaccine 1 year previously.

Authors+Show Affiliations

Department of Medicine, Chulalongkorn University, and the Queen Saovabha Memorial Institute (World Health Organization Collaborating Center for Research in Rabies Pathogenesis and Prevention), the Thai Red Cross Society, Bangkok.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10452642

Citation

Tantawichien, T, et al. "Antibody Response After a Four-site Intradermal Booster Vaccination With Cell-culture Rabies Vaccine." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 28, no. 5, 1999, pp. 1100-3.
Tantawichien T, Benjavongkulchai M, Limsuwan K, et al. Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Clin Infect Dis. 1999;28(5):1100-3.
Tantawichien, T., Benjavongkulchai, M., Limsuwan, K., Khawplod, P., Kaewchompoo, W., Chomchey, P., & Sitprija, V. (1999). Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 28(5), 1100-3.
Tantawichien T, et al. Antibody Response After a Four-site Intradermal Booster Vaccination With Cell-culture Rabies Vaccine. Clin Infect Dis. 1999;28(5):1100-3. PubMed PMID: 10452642.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. AU - Tantawichien,T, AU - Benjavongkulchai,M, AU - Limsuwan,K, AU - Khawplod,P, AU - Kaewchompoo,W, AU - Chomchey,P, AU - Sitprija,V, PY - 1999/8/19/pubmed PY - 1999/8/19/medline PY - 1999/8/19/entrez SP - 1100 EP - 3 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 28 IS - 5 N2 - The current World Health Organization recommendation for booster vaccination of previously immunized individuals with potential exposure to rabies is two doses of vaccine intramuscularly or intradermally on days 0 and 3. We report responses to two types of postexposure treatment of healthy individuals who had received preexposure rabies vaccination 1 year previously. Group A individuals received four intradermal doses (one-fifth of the diluent volume of vaccine per dose) on day 0, and group B individuals received two intramuscular doses on days 0 and 3. Immunogenicity of the two booster regimens was assessed by titrating the amount of neutralizing antibody (Nab). We found that the booster doses of vaccine produced remarkable responses in all subjects. Nab titers of > or = 0.5 IU/mL (acceptable antibody level for protection against rabies) were detected in all subjects on day 14, and they were shown to be consistently high 1 year after the booster vaccination. We also found that the Nab titers for group A were significantly higher (two- to eightfold) than those for group B on days 5, 14, 150, and 360 after the initial booster vaccination (P < .05). Our study shows that the four-site intradermal booster regimen with use of one-fifth of the diluent volume of cell-culture rabies vaccine on day 0 is associated with a significantly higher antibody response than is the conventional booster regimen for subsequent postexposure rabies treatment of individuals who have received preexposure rabies vaccination with cell-culture rabies vaccine 1 year previously. SN - 1058-4838 UR - https://www.unboundmedicine.com/medline/citation/10452642/Antibody_response_after_a_four_site_intradermal_booster_vaccination_with_cell_culture_rabies_vaccine_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/514737 DB - PRIME DP - Unbound Medicine ER -